Xeris Biopharma Holdings Inc reports results for the quarter ended March 31 - Earnings Summary

• Xeris Biopharma Holdings Inc XERS.OQ reported a quarterly adjusted loss of 6 cents​​ per share for the quarter ended March 31, higher than the same quarter last year, when the company reported EPS of -14 cents. The mean expectation of six analysts for the quarter was for a loss of 5 cents per share. Wall Street expected results to range from -8 cents to 1 cents per share.

• Revenue rose 47.9% to $60.12 million from a year ago; analysts expected $57.61 million.

• Xeris Biopharma Holdings Inc's reported EPS for the quarter was a loss of 6 cents​.

• The company reported a quarterly loss of $9.22 million.

• Xeris Biopharma Holdings Inc shares had fallen by 18.4% this quarter and gained 32.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 20% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Xeris Biopharma Holdings Inc is $6.25

This summary was machine generated from LSEG data May 8 at 02:21 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)